Two is better than one: Complementing oncolytic virotherapy with gemcitabine to potentiate antitumor immune responses

Abstract

Oncolytic viruses (OVs) preferentially infect and kill cancer cells. Additionally, OV-induced immune responses subvert cancer-associated immunosuppression and promote antitumor immunity. We have recently demonstrated that the complementation of oncolytic virotherapy with gemcitabine accentuates its immunostimulatory effects, hence exerting superior antineoplastic activity. © 2014 Landes Bioscience.